FR2951172B1 - Derives pyrazolopyridines en tant qu'agent anticancereux - Google Patents

Derives pyrazolopyridines en tant qu'agent anticancereux

Info

Publication number
FR2951172B1
FR2951172B1 FR0957140A FR0957140A FR2951172B1 FR 2951172 B1 FR2951172 B1 FR 2951172B1 FR 0957140 A FR0957140 A FR 0957140A FR 0957140 A FR0957140 A FR 0957140A FR 2951172 B1 FR2951172 B1 FR 2951172B1
Authority
FR
France
Prior art keywords
cancer agent
pyrazolopyridine derivatives
pyrazolopyridine
derivatives
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0957140A
Other languages
English (en)
French (fr)
Other versions
FR2951172A1 (fr
Inventor
Karim Bedjeguelal
Remi Rabot
El Bachir Kaloun
Patrice Mayer
Arnaud Marchand
Nicolas Rahier
Philippe Schambel
Hugues Bienayme
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Priority to FR0957140A priority Critical patent/FR2951172B1/fr
Priority to EP10770774.7A priority patent/EP2488519B1/en
Priority to US13/500,757 priority patent/US8889711B2/en
Priority to JP2012533621A priority patent/JP5833010B2/ja
Priority to PCT/EP2010/065346 priority patent/WO2011045344A1/en
Publication of FR2951172A1 publication Critical patent/FR2951172A1/fr
Application granted granted Critical
Publication of FR2951172B1 publication Critical patent/FR2951172B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR0957140A 2009-10-13 2009-10-13 Derives pyrazolopyridines en tant qu'agent anticancereux Expired - Fee Related FR2951172B1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FR0957140A FR2951172B1 (fr) 2009-10-13 2009-10-13 Derives pyrazolopyridines en tant qu'agent anticancereux
EP10770774.7A EP2488519B1 (en) 2009-10-13 2010-10-13 Pyrazolopyridine derivatives as anticancer agent
US13/500,757 US8889711B2 (en) 2009-10-13 2010-10-13 Pyrazolopyridine derivatives as anticancer agent
JP2012533621A JP5833010B2 (ja) 2009-10-13 2010-10-13 抗癌剤としてのピラゾロピリジン誘導体
PCT/EP2010/065346 WO2011045344A1 (en) 2009-10-13 2010-10-13 Pyrazolopyridine derivatives as anticancer agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0957140A FR2951172B1 (fr) 2009-10-13 2009-10-13 Derives pyrazolopyridines en tant qu'agent anticancereux

Publications (2)

Publication Number Publication Date
FR2951172A1 FR2951172A1 (fr) 2011-04-15
FR2951172B1 true FR2951172B1 (fr) 2014-09-26

Family

ID=42112290

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0957140A Expired - Fee Related FR2951172B1 (fr) 2009-10-13 2009-10-13 Derives pyrazolopyridines en tant qu'agent anticancereux

Country Status (5)

Country Link
US (1) US8889711B2 (enExample)
EP (1) EP2488519B1 (enExample)
JP (1) JP5833010B2 (enExample)
FR (1) FR2951172B1 (enExample)
WO (1) WO2011045344A1 (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
DE102011105469A1 (de) * 2011-06-24 2012-12-27 Merck Patent Gmbh 7-Azaindolderivate
EP2760862B1 (en) * 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
FR2984325A1 (fr) * 2011-12-14 2013-06-21 Sanofi Sa Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique
US10138235B2 (en) 2011-12-14 2018-11-27 Sanofi Pyrazolopyridine derivatives, preparation process therefor and therapeutic use thereof
FR2985257B1 (fr) * 2011-12-28 2014-02-14 Sanofi Sa Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique
CN103214470A (zh) * 2012-01-18 2013-07-24 杨更亮 酮类与吲哚衍生物反应合成的新型抗癌化合物
WO2013167403A1 (en) 2012-05-09 2013-11-14 Sanofi Substituted 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine derivatives as kinase inhibitors
SMT201700146T1 (it) 2012-06-13 2017-05-08 Incyte Holdings Corp Composti triciclici sostituiti come inibitori di fgfr
WO2013187462A1 (ja) 2012-06-14 2013-12-19 第一三共株式会社 ピペリジニルピラゾロピリジン誘導体
EP2867236B1 (en) 2012-06-29 2017-06-14 Pfizer Inc Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) * 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
US9045477B2 (en) 2013-03-15 2015-06-02 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
WO2014144747A1 (en) 2013-03-15 2014-09-18 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
CA2909207C (en) 2013-04-19 2021-11-02 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
EP3083618B1 (en) 2013-12-17 2018-02-21 Pfizer Inc Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
JP6713982B2 (ja) 2014-07-24 2020-06-24 ファイザー・インク ピラゾロピリミジン化合物
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10221172B2 (en) 2015-01-13 2019-03-05 Vanderbilt University Benzothiazole and benzisothiazole-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
UA121669C2 (uk) 2015-02-20 2020-07-10 Інсайт Корпорейшн Біциклічні гетероцикли як інгібітори fgfr
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
WO2016205460A1 (en) * 2015-06-16 2016-12-22 Nantbioscience, Inc. Polycyclic derivatives targeting ral gtpases and their therapeutical applications
ES2857081T3 (es) * 2015-07-16 2021-09-28 Array Biopharma Inc Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
CN108137586B (zh) 2015-09-14 2021-04-13 辉瑞大药厂 作为LRRK2抑制剂的新颖咪唑并[4,5-c]喹啉和咪唑并[4,5-c][1,5]萘啶衍生物
NZ750414A (en) 2016-07-05 2023-02-24 Guangzhou Maxinovel Pharmaceuticals Co Ltd Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
ES2948194T3 (es) 2017-01-18 2023-09-01 Array Biopharma Inc Compuestos de pirazolo[1,5-a]pirazina sustituida como inhibidores de la cinasa RET
AR111473A1 (es) * 2017-04-19 2019-07-17 Sumitomo Chemical Co Método para la preparación de compuesto de piridina
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
KR20200036004A (ko) 2017-08-01 2020-04-06 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 키나아제 억제제로서 피라졸로 및 트리아졸로 비시클릭 화합물
WO2019128918A1 (zh) 2017-12-29 2019-07-04 广州再极医药科技有限公司 芳香乙烯或芳香乙基类衍生物、其制备方法、中间体、药物组合物及应用
US11603374B2 (en) 2018-01-18 2023-03-14 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CA3087578C (en) 2018-01-18 2023-08-08 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
TW201932464A (zh) 2018-01-18 2019-08-16 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑基[4,3-c]吡啶化合物
SG11202010882XA (en) 2018-05-04 2020-11-27 Incyte Corp Salts of an fgfr inhibitor
SMT202400507T1 (it) 2018-05-04 2025-01-14 Incyte Corp Forme solide di un inibitore di fgfr e procedimenti per preparare le stesse
EP3849986B1 (en) 2018-09-10 2022-06-08 Array Biopharma, Inc. Fused heterocyclic compounds as ret kinase inhibitors
CN113498352A (zh) 2019-01-23 2021-10-12 施万生物制药研发Ip有限责任公司 作为jak抑制剂的咪唑并[1,5-a]吡啶、1,2,4-三唑并[4,3-a]吡啶和咪唑并[1,5-a]吡嗪
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CA3157361A1 (en) 2019-10-14 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021113462A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
US11897891B2 (en) 2019-12-04 2024-02-13 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CA3215903A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
EP4352060A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
TW202423428A (zh) * 2022-09-29 2024-06-16 香港商英矽智能科技知識產權有限公司 Tead抑制劑及其使用方法
WO2025190406A1 (en) * 2024-03-15 2025-09-18 Insilico Medicine Ip Limited Tead inhibitor combinations and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3687516T2 (de) * 1985-12-13 1993-07-29 American Cyanamid Co Neue kondensierte pyridinverbindungen, zwischenverbindungen fuer die herstellung und ihre verwendung als herbizide wirkstoffe.
US4822799A (en) * 1988-01-27 1989-04-18 Sandoz Pharm. Corp. Pyrazolopyridine analogs of mevalonolactone and derivatives thereof useful for inhibiting cholesterol biosynthesis in mammals
WO2003068773A1 (en) * 2002-02-12 2003-08-21 Glaxo Group Limited Pyrazolopyridine derivatives
CA2494785A1 (en) 2002-08-07 2004-02-19 Mitsubishi Pharma Corporation Dihydropyrazolopyridine compounds
US20040142978A1 (en) * 2002-12-12 2004-07-22 Pharmacia Corporation Aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase-2
ATE481402T1 (de) * 2003-02-27 2010-10-15 Palau Pharma Sa Pyrazolopyridin-derivate
US7872014B2 (en) * 2003-07-23 2011-01-18 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
EP1763528B1 (en) * 2004-07-05 2008-11-26 Astellas Pharma Inc. Pyrazolopyridine derivatives
JP2009506004A (ja) * 2005-08-25 2009-02-12 エフ．ホフマン−ラ ロシュ アーゲー ｐ３８ＭＡＰキナーゼ阻害剤としての縮合ピラゾール
WO2009006580A1 (en) * 2007-07-05 2009-01-08 Cv Therapeutics, Inc. Optionally condensed dihydropyridine, dihydropyrimidine and dihydropyrane derivatives acting as late sodium channel blockers
US20100113415A1 (en) 2008-05-29 2010-05-06 Rajapakse Hemaka A Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer

Also Published As

Publication number Publication date
EP2488519A1 (en) 2012-08-22
EP2488519B1 (en) 2015-06-10
JP5833010B2 (ja) 2015-12-16
JP2013507425A (ja) 2013-03-04
US20120245170A1 (en) 2012-09-27
WO2011045344A1 (en) 2011-04-21
US8889711B2 (en) 2014-11-18
FR2951172A1 (fr) 2011-04-15

Similar Documents

Publication Publication Date Title
FR2951172B1 (fr) Derives pyrazolopyridines en tant qu'agent anticancereux
FR23C1039I2 (fr) Derives de piperidinone carboxamide azaindane en tant qu'antagonistes du recepteur cgrp
EP2890691A4 (en) BENZIMIDAZOLE DERIVATIVES AS ICT INHIBITORS
BRPI1009118A2 (pt) 3h-imidazo[4,5-c] piridina-6-carboxamidas como agentes anti-inflamatórios
EP2320737A4 (en) PYRAZOLO- [1,5-A] -PYRIDINE AS MARK HEMMER
BRPI0919292A2 (pt) 3h-imidazo[4,5-b] piridina-6-carboxamidas como agentes anti-inflamatórios
AP3862A (en) Novel benzimidazole derivatives as ep4 antagonists
SMT201500316B (it) Derivati di benzotiazolo come agenti anticancro
FR3000492B1 (fr) Nouveaux derives azaindole en tant qu'inhibiteurs multikinases
EP2863914A4 (en) PYRAZOLYL DERIVATIVES AS SYK-HEMMER
EP2667874A4 (en) MTOR KINASE HEMMER AS ANTIVIRUS AGENT
EP2888007A4 (en) NOVEL BENZIMIDAZOLTETRAHYDROFURANDERIVATE
EP2654748A4 (en) INDAZONE DERIVATIVES AS ERK HEMMER
DK2401270T3 (da) Pyrazolderivater anvendt som CCR4-receptorantagonister.
EP2685992A4 (en) AMINOCHINOLINE AS A KINASEHEMMER
IT1393337B1 (it) Sintesi di (4as, 7as)-ottaidro-1h-pirrolo[3,4-b]piridina
EP2346866A4 (en) BETA-CARBOLINE-SULPHONYL HARVESIDE DERIVATIVES AS EP4-RECEPTOR ANTAGONISTS
ZA201403195B (en) Pharmaceutical compositions of hydrophobic camptothecin derivatives
BRPI1008173A2 (pt) "derivados de piridina espiroindolinona"
IL207972A0 (en) Pyridin-2-yl derivatives as immunomodulating agents
BR112013013837A2 (pt) derivados de substituição de imidazoquinolina
EP2922543A4 (en) SUBSTITUTED PYRIDONE DERIVATIVES AS PDE10 INHIBITORS
EP2685824A4 (en) INDUSTRIAL DERIVATIVES USED AS CCR2 ANTAGONISTS
EP2461805A4 (en) SPECTINAMID AS A MEDIUM AGAINST TUBERCULOSIS
EP2797909A4 (en) Novel imidazopyridine derivatives as a tyrosine kinin inhibitor

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8

ST Notification of lapse

Effective date: 20180629